Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.

Low, LE; Kong, CK; Yap, W-H; Siva, SP; Gan, SH; Siew, WS; Ming, LC; Lai-Foenander, AS; Chang, SK; Lee, W-L; Wu, Y; Khaw, K-Y; Ong, YS; Tey, BT; Singh, SK; Dua, K; Chellappan, DK; Goh, B-H

Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.

Low, LE Kong, CK Yap, W-H Siva, SP Gan, SH Siew, WS Ming, LC Lai-Foenander, AS Chang, SK Lee, W-L Wu, Y Khaw, K-Y Ong, YS Tey, BT Singh, SK Dua, K

Chellappan, DK Goh, B-H

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Chem Biol Interact, 2023, pp. 110750
Issue Date:: 2023-10-13

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (3.98 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Low, LE
dc.contributor.author	Kong, CK
dc.contributor.author	Yap, W-H
dc.contributor.author	Siva, SP
dc.contributor.author	Gan, SH
dc.contributor.author	Siew, WS
dc.contributor.author	Ming, LC
dc.contributor.author	Lai-Foenander, AS
dc.contributor.author	Chang, SK
dc.contributor.author	Lee, W-L
dc.contributor.author	Wu, Y
dc.contributor.author	Khaw, K-Y
dc.contributor.author	Ong, YS
dc.contributor.author	Tey, BT
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Chellappan, DK
dc.contributor.author	Goh, B-H
dc.date.accessioned	2023-10-26T01:42:19Z
dc.date.available	2023-10-05
dc.date.available	2023-10-26T01:42:19Z
dc.date.issued	2023-10-13
dc.identifier.citation	Chem Biol Interact, 2023, pp. 110750
dc.identifier.issn	0009-2797
dc.identifier.issn	1872-7786
dc.identifier.uri	http://hdl.handle.net/10453/172863
dc.description.abstract	Hydroxychloroquine (HCQ) is a unique class of medications that has been widely utilized for the treatment of cancer. HCQ plays a dichotomous role by inhibiting autophagy induced by the tumor microenvironment (TME). Preclinical studies support the use of HCQ for anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they sensitize tumor cells to drugs, potentiating the therapeutic activity. However, clinical evidence has suggested poor outcomes for HCQ due to various obstacles, including non-specific distribution, low aqueous solubility and low bioavailability at target sites, transport across tissue barriers, and retinal toxicity. These issues are addressable via the integration of HCQ with nanotechnology to produce HCQ-conjugated nanomedicines. This review aims to discuss the pharmacodynamic, pharmacokinetic and antitumor properties of HCQ. Furthermore, the antitumor performance of the nanoformulated HCQ is also reviewed thoroughly, aiming to serve as a guide for the HCQ-based enhanced treatment of cancers. The nanoencapsulation or nanoconjugation of HCQ with nanoassemblies appears to be a promising method for reducing the toxicity and improving the antitumor efficacy of HCQ.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Chem Biol Interact
dc.relation.isbasedon	10.1016/j.cbi.2023.110750
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0601 Biochemistry and Cell Biology
dc.subject.classification	Toxicology
dc.subject.classification	3101 Biochemistry and cell biology
dc.title	Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.
dc.type	Journal Article
utslib.location.activity	Ireland
utslib.for	0601 Biochemistry and Cell Biology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	open_access	*
dc.date.updated	2023-10-26T01:42:10Z
pubs.publication-status	Published online

Abstract:

Hydroxychloroquine (HCQ) is a unique class of medications that has been widely utilized for the treatment of cancer. HCQ plays a dichotomous role by inhibiting autophagy induced by the tumor microenvironment (TME). Preclinical studies support the use of HCQ for anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they sensitize tumor cells to drugs, potentiating the therapeutic activity. However, clinical evidence has suggested poor outcomes for HCQ due to various obstacles, including non-specific distribution, low aqueous solubility and low bioavailability at target sites, transport across tissue barriers, and retinal toxicity. These issues are addressable via the integration of HCQ with nanotechnology to produce HCQ-conjugated nanomedicines. This review aims to discuss the pharmacodynamic, pharmacokinetic and antitumor properties of HCQ. Furthermore, the antitumor performance of the nanoformulated HCQ is also reviewed thoroughly, aiming to serve as a guide for the HCQ-based enhanced treatment of cancers. The nanoencapsulation or nanoconjugation of HCQ with nanoassemblies appears to be a promising method for reducing the toxicity and improving the antitumor efficacy of HCQ.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172863